Covid-19 Treatment Market

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In Covid-19 Treatment Market , we study all treatment method for Covid-19.

Covid-19 Treatment Market contains market size and forecasts of Covid-19 Treatment in Global, including the following market information:

Global Covid-19 Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Covid-19 Treatment market was valued at 14310 million in 2021 and is projected to reach US$ 41 million by 2028, at a CAGR of -56.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Life Support Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Covid-19 Treatment include Cadila Healthcare, Johnson & Johnson, ImmunoPrecise, Novartis, AstraZeneca, Cipla, AbbVie, Bayer and Regeneron Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Covid-19 Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Covid-19 Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Covid-19 Treatment Market Segment Percentages, by Type, 2021 (%)

Life Support

Antiviral Medicine

Antibody Treatments

Others

Global Covid-19 Treatment Market, by End User, 2017-2022, 2023-2028 ($ millions)

Global Covid-19 Treatment Market Segment Percentages, by End User, 2021 (%)

Children

Adult

Global Covid-19 Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Covid-19 Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Covid-19 Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Covid-19 Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Cadila Healthcare

Johnson & Johnson

ImmunoPrecise

Novartis

AstraZeneca

Cipla

AbbVie

Bayer

Regeneron Pharmaceuticals

Ascletis Pharma

GlaxoSmithKline

Gilead Sciences

Pharmstandard

Fujifilm Holdings

Zhejiang Hisun Pharmaceutical Co. Ltd

Roche

Sanofi

Pfizer

Eli Lilly